Most Read Articles
Roshini Claire Anthony, 2 days ago

The addition of the glucagon-like peptide-1 analogue semaglutide to standard of care resulted in sustained reduction in weight and waist circumference in individuals with type 2 diabetes (T2D) with high cardiovascular risk, according to the phase III SUSTAIN 6* trial presented at EASD 2017.

6 days ago
There appears to be an association between waterpipe tobacco smoking and gastro-oesophageal reflux disease (GERD), which is a known risk factor for oesophageal adenocarcinoma, a study has shown.
4 days ago
The additional use of intermittent low-energy diet (LED) or daily meal replacements after a mean 10-percent weight loss and 1-year maintenance effectively maintains weight loss in obese patients with knee osteoarthritis for 3 years, according to a recent study.
15 Sep 2017
A recent study has found that food bolus impaction or strictures predict most episodes of oesophageal perforation, a rare but serious complication of eosinophilic esophagitis (EoE) that occurs in about 2 percent of cases. This suggests that patients with fibrostenotic disease due to longer duration of symptoms are at increased risk.

Mesalazine 1,600-mg formulation noninferior to 400 mg for induction treatment of UC

01 Aug 2017

In patients with ulcerative colitis (UC), induction treatment with 3.2 mg mesalazine using two 1,600 mg tablets once-daily is as good as using four 400 mg tablets twice-daily, according to the results of a noninferority trial.

A total of 817 patients with mild-to-moderate active UC (Mayo Clinic Score >5) were treated with 3.2 g of oral mesalazine, administered as either two 1,600 mg tablets once or four 400 mg tablets twice daily. Outcomes investigated were induction of clinical and endoscopic remission at week 8. Based on response, open-label treatment with the 1,600 mg tablet continued for 26 to 30 weeks. Predictors of treatment response were also examined.

At week 8, remission occurred in 22.4 percent of patients receiving the 1,600 mg formulation and in 24.6 percent of those receiving the 400 mg formulation (absolute difference, −2.2 percent; 95 percent CI, −8.1 to 3.8; noninferiority, p=0.005). Clinical remission was significantly associated with endoscopic and histopathologic disease activity (p=0.022 and p=0.042), leucocyte concentration (p=0.014), and age (p=0.023).

At week 38, 296 of 675 patients (43.9 percent) who continued treatment with the 1,600 mg formulation were in remission, including 142 of 202 patients (70.3 percent) who received a reduced dose of mesalazine (1.6 g/d). Overall incidence of serious adverse events was low.

Oral mesalazine is the most commonly prescribed medication for patients with mild-to-moderate UC. While multitablet regimens administered two to four times daily have been shown to be safe and effective, a high-concentration formulation was developed to improve dosing convenience and ensure consistent drug release within the colon. [Gastroenterology 2015;148:1035-1058; Cochrane Database Syst Rev 2016;4:CD000543]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

The addition of the glucagon-like peptide-1 analogue semaglutide to standard of care resulted in sustained reduction in weight and waist circumference in individuals with type 2 diabetes (T2D) with high cardiovascular risk, according to the phase III SUSTAIN 6* trial presented at EASD 2017.

6 days ago
There appears to be an association between waterpipe tobacco smoking and gastro-oesophageal reflux disease (GERD), which is a known risk factor for oesophageal adenocarcinoma, a study has shown.
4 days ago
The additional use of intermittent low-energy diet (LED) or daily meal replacements after a mean 10-percent weight loss and 1-year maintenance effectively maintains weight loss in obese patients with knee osteoarthritis for 3 years, according to a recent study.
15 Sep 2017
A recent study has found that food bolus impaction or strictures predict most episodes of oesophageal perforation, a rare but serious complication of eosinophilic esophagitis (EoE) that occurs in about 2 percent of cases. This suggests that patients with fibrostenotic disease due to longer duration of symptoms are at increased risk.